NEWS 92 FEED & ADDITIVE MAGAZINE October 2023 Zivo Bioscience, Inc., a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announced positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statistically significant positive outcomes in the treated groups. Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billion (Re-calculating the Cost of Coccidiosis Zivo Bioscience explains new trial results on its non-antibiotic product As the global authority on animal health, the World Organisation for Animal Health (WOAH) has been collecting information on the use of antimicrobials in animals since 2015. A report has been published every year to provide access to this crucial and growing set of information and has highlighted steady efforts in the animal health sector worldwide. The latest report, which has been recently released, showcased that global antimicrobial use in animals has declined by 13% in 3 years, marking again a significant shift in the continuous efforts to preserve the efficacy of these critical medicines. Antimicrobial drugs, such as antibiotics, paved the way for better living conditions for humans and animals. Before the discovery of penicillin by Alexander Fleming in 1928, infections due to minor cuts could lead to bloodstream infections or death. Yet, today, these life-saving drugs are losing their efficacy due to their misuse and overuse in different sectors. The phenomenon is known as ‘antimicrobial resistance’. It can originate in animal, human, or plant populations, and then pose a threat to all the other species. In this context, monitoring how, when, and which antimicrobials are used becomes critical to identify patterns and trends. Ultimately, this can facilitate decision-making and support the implementation of measures to ensure the optimal and sustainable use of these key medicines. "Less than 20% of antimicrobials used in animals in 2019 were of the highest priority and critical importance for human health. Collective efforts towards responsible use across all sectors are of utmost importance considering that these medicines are the sole therapy or one of few alternatives to treat life-threatening human diseases. It is important to highlight that, in the same year, an estimated 4 million human deaths were linked to antimicrobial resistance," said Dr Javier Yugueros-Marcos, Head of the Antimicrobial Resistance and Veterinary Products Department, WOAH. Read more>> New report reveals global decrease in antimicrobial use
RkJQdWJsaXNoZXIy MTUxNjkxNQ==